118488-08-7

Basic information

• Product Name: 1-(Thiophen-3-yl)ethanamine
• Synonyms: 1-(3-Thienyl)ethanaMine;1-(THIOPHEN-3-YL)ETHAN-1-AMINE;[1-(Thien-3-yl)ethyl]amine;1-(Thiophen-3-yl)ethanamine;1-(3-thienyl)ethanamine(SALTDATA: FREE);[1-(3-Thienyl)ethyl]amine
• CAS NO: 118488-08-7
• Molecular Formula: C₆H₉NS
• Molecular Weight: 127.21
• Mol File: 118488-08-7.mol

Chemical Properties

• Boiling Point: 200.242°C at 760 mmHg
• Flash Point: 74.904°C
• Appearance: /
• Density: 1.095g/cm³
• Vapor Pressure: 0.328mmHg at 25°C
• Refractive Index: 1.563
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 10.04±0.29(Predicted)
• CAS DataBase Reference: 1-(Thiophen-3-yl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(Thiophen-3-yl)ethanamine(118488-08-7)
• EPA Substance Registry System: 1-(Thiophen-3-yl)ethanamine(118488-08-7)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• RIDADR: UN 2811 6.1 / PGIII
• Hazardous Substances Data: 118488-08-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
1-(Thiophen-3-yl)ethanamine is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be a versatile building block for the creation of new drugs with potential applications in treating a range of medical conditions.
Used in Organic Synthesis:
As an amine, 1-(Thiophen-3-yl)ethanamine is utilized in organic synthesis for the preparation of a variety of chemical products. Its reactivity and functional groups make it suitable for use in the formation of complex organic molecules.
Used in the Development of Therapeutics for Central Nervous System Disorders:
1-(Thiophen-3-yl)ethanamine is employed as a starting material in the development of potential therapeutics for central nervous system disorders. Its biological activities and chemical properties make it a promising candidate for the treatment of such conditions.
Used in the Development of Therapeutics for Neurodegenerative Diseases:
Similarly, 1-(Thiophen-3-yl)ethanamine is used in the research and development of therapeutics aimed at treating neurodegenerative diseases. Its potential role in modulating biological pathways relevant to these diseases makes it an important compound in the search for effective treatments.
Used in Chemical Production:
1-(Thiophen-3-yl)ethanamine serves as an intermediate in the production of other chemicals, contributing to the synthesis of a wide range of chemical products across various industries.

InChI:InChI=1/C6H9NS/c1-5(7)6-2-3-8-4-6/h2-5H,7H2,1H3

Upstream product

• 118488-07-6 1-(3-thienyl)ethylazide 
• 1468-83-3 1-(thiophen-3-yl)-ethanone 
• 56423-56-4 3-(1-chloroethyl)thiophene 
• 14861-60-0 1-(thiophen-3-yl)ethan-1-ol 

Relevant articles and documents

Direct reductive amination of ketones with ammonium salt catalysed by Cp*Ir(iii) complexes bearing an amidato ligand

A series of half-sandwich Ir(iii) complexes1-6bearing an amidato bidentate ligand were conveniently synthesized and applied to the catalytic Leuckart-Wallach reaction to produce racemic α-chiral primary amines. With 0.1 mol% of complex1, a broad range of ketones, including aryl ketones, dialkyl ketones, cyclic ketones, α-keto acids, α-keto esters and diketones, could be transformed to their corresponding primary amines with moderate to excellent yields (40%-95%). Asymmetric transformation was also attempted with chiral Ir complexes3-6, and 16% ee of the desired primary amine was obtained. Despite the unsatisfactory enantio-control achieved so far, the current exploration might stimulate more efforts towards the discovery of better chiral catalysts for this challenging but important transformation.

Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity

Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC therapeutic index are desired. Peptide-based ADC linkers that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells. If the linker can be preferentially hydrolyzed by tumor-specific proteases, safety margin may improve. However, the use of peptide-based linkers limits our ability to modulate protease specificity. Here we report the structure-guided discovery of novel, nonpeptidic ADC linkers. We show that a cyclobutane-1,1-dicarboxamide-containing linker is hydrolyzed predominantly by cathepsin B while the valine-citrulline dipeptide linker is not. ADCs bearing the nonpeptidic linker are as efficacious and stable in vivo as those with the dipeptide linker. Our results strongly support the application of the peptidomimetic linker and present new opportunities for improving the selectivity of ADCs.

TETRAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF

This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.

THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is a group of formula A or formula B, and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.

OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula 1: or a pharmaceutically acceptable salt thereof, wherein, X, Y, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

INDOLE, INDAZOLE AND BENZIMIDAZOLE ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, X, Y, Z, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.

Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists

Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted tetrazolyl, R2 is optionally substituted phenyl, optionally substituted pyridinyl or optionally substituted thienyl, and R3, R4, R5 and R6 are as defined herein. Also provided are methods of using the compounds for treating diseases associated with the P2X3 and/or a P2X2/3 receptor antagonist and methods of making the compounds.

THIAZOLE AND OXAZOLE-SUBSTITUTED ARYLAMIDES

Compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein: R1 is a group of formula A or formula B; and X, R2, R3, R4, R5, R6, Ra and Rb are as defined herein. Also provided are methods of using the compounds for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist and methods of making the subject compounds.

Thienopyridines useful as cardiovascular agents

The synthesis of thienopyridine derivatives is described. The novel thienopyridine derivatives are cardiotonic agents and renal vasodilating agents. The compounds are useful as cardiovascular agents.